Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Gabriel Helmlinger"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionIn vivo T cell migration has been of interest to scientists for the past 60 years. T cell kinetics are important in the understanding of the immune response to infectious agents. More recently, adoptive T cell therapies have proven to be
Externí odkaz:
https://doaj.org/article/104efaa5aded44e295627f1eaa31bc94
Autor:
Yaroslav Ugolkov, Antonina Nikitich, Cristina Leon, Gabriel Helmlinger, Kirill Peskov, Victor Sokolov, Alina Volkova
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The research & development (R&D) of novel therapeutic agents for the treatment of autoimmune diseases is challenged by highly complex pathogenesis and multiple etiologies of these conditions. The number of targeted therapies available on the market i
Externí odkaz:
https://doaj.org/article/73c9785dc2df4d8898dd4013a1d53edf
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe thymus plays a central role in shaping human immune function. A mechanistic, quantitative description of immune cell dynamics and thymic output under homeostatic conditions and various patho-physiological scenarios are of particular int
Externí odkaz:
https://doaj.org/article/21c1dcc9373a424bb01e946ea35bb480
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2024)
AimsTo develop a model-informed methodology for the optimization of the Major Adverse Cardiac Events (MACE) composite endpoint, based on a model-based meta-analysis across anti-hypercholesterolemia trials of statin and anti-PCSK9 drugs.Methods and re
Externí odkaz:
https://doaj.org/article/8df75c8f252c406bb8f8b9d40ed9dcc4
Autor:
Kirill Zhudenkov, Sergey Gavrilov, Alina Sofronova, Oleg Stepanov, Nataliya Kudryashova, Gabriel Helmlinger, Kirill Peskov
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 4, Pp 425-437 (2022)
Abstract Clinical trials investigate treatment endpoints that usually include measurements of pharmacodynamic and efficacy biomarkers in early‐phase studies and patient‐reported outcomes as well as event risks or rates in late‐phase studies. In
Externí odkaz:
https://doaj.org/article/3586fb557e354f93bb4b2be977de2eae
Publikováno v:
Frontiers in Applied Mathematics and Statistics, Vol 8 (2022)
Anti CTLA-4 therapy is aimed at blocking the Cytotoxic T-lymphocyte antigen-4 (CTLA-4), a key cancer immunity cycle checkpoint. The mechanism of action of CTLA-4 may be described as a dynamic competition for the B7 ligand which, subsequently, interfe
Externí odkaz:
https://doaj.org/article/40dafde082c041508077a8aed1990c1e
Autor:
Victor Sokolov, Tatiana Yakovleva, Lulu Chu, Weifeng Tang, Peter J. Greasley, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W. Boulton, Robert C. Penland
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 4, Pp 222-229 (2020)
The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative
Externí odkaz:
https://doaj.org/article/4f5804238a5a4ff3b4cb5e7de0343122
Autor:
Veronika Voronova, Victor Sokolov, Amani Al-Khaifi, Sara Straniero, Chanchal Kumar, Kirill Peskov, Gabriel Helmlinger, Mats Rudling, Bo Angelin
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 10, Iss 1, Pp 149-170 (2020)
Background & Aims: Disturbances of the enterohepatic circulation of bile acids (BAs) are seen in a number of clinically important conditions, including metabolic disorders, hepatic impairment, diarrhea, and gallstone disease. To facilitate the explor
Externí odkaz:
https://doaj.org/article/018c0db56b184ba3b01bdf259b968933
Autor:
Victor Sokolov, Gabriel Helmlinger, Catarina Nilsson, Kirill Zhudenkov, Stanko Skrtic, Bengt Hamrén, Kirill Peskov, Eva Hurt-Camejo, Rasmus Jansson-Löfmark
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 9, Pp 1610-1621 (2019)
Since the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as an attractive target in the treatment of hypercholesterolemia, multiple anti-PCSK9 therapeutic modalities have been pursued in drug development. The objective of this res
Externí odkaz:
https://doaj.org/article/bd39b188292347dca7350be24e8f0568
Autor:
Gabriel Helmlinger, Rachel Burga, Stanley Tam, Mithun Khattar, Scott Lajoie, Kyle Pedro, Colleen Foley, Alonso Villasmil Ocando, Jack Tremblay, Benjamin Primack, Meghan Langley, Dan Thornton, Emily Brideau, Theresa Ross, Gwen Wilmes, Sunandan Saha, Jeremy Tchaicha, Dhruv Sethi, Michelle Ols, Gary Vanasse, Shyam Subramanian, Jan ter Meulen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/96bcf551331a468aa219481d0e648459